Biotechnology - Rare diseases, Oncology

Filter

Current filters:

Rare diseasesOncology

Popular Filters

bluebird bio poised to advance gene therapy pipeline

bluebird bio poised to advance gene therapy pipeline

02-09-2014

US clinical-stage biotech firm bluebird bio is advancing a pipeline focused on gene therapy, a rapidly…

Biotechnologybluebird bioCelgene Corp.OncologyRare diseasesResearch

Oncothyreon acquires Alpine Biosciences

Oncothyreon acquires Alpine Biosciences

12-08-2014

US biotech firm Oncothyreon says that it has acquired Alpine Biosciences, of Seattle, Washington, a privately…

Alpine BiosciencesBiotechnologyBusiness FinanceImmunotherapyMedicineMergers & AcquisitionsOncologyOncothyreonRare diseasesUSA

US orphan status for Mirati’s mocetinostat and Alexion’s Soliris

US orphan status for Mirati’s mocetinostat and Alexion’s Soliris

17-06-2014

USA-based Mirati Therapeutics has been granted Orphan Drug designation by the US Food and Drug Administration…

BiotechnologyOncologyRare diseasesRegulation

Cell Therapeutics reaches price deal with German insurer GKV-SV on Pixuvri

Cell Therapeutics reaches price deal with German insurer GKV-SV on Pixuvri

04-12-2013

US biotech firm Cell Therapeutics has concluded an agreement with the Germany’s National Association…

BiotechnologyCell TherapeuticsOncologyPixuvriPricingRare diseases

Progenics relaunches registrational trial of Azedra in pheochromocytomas

25-11-2013

USA-based Progenics Pharmaceuticals says it is resuming a Phase IIb clinical study of safety and efficacy…

AzedraBiotechnologyOncologyProgenics PharmaceuticalsRare diseasesResearch

SOBI restructures Kineret and Kepivance deals

09-09-2013

Swedish Orphan Biovitrum (STO: SOBI) said this morning that it has acquired the full rights to develop…

AmgenAnti-Arthritics/RheumaticsBiotechnologyKepivanceKineretLicensingOncologyPharmaceuticalRare diseasesSwedish Orphan Biovitrum

UK's NICE calls for more data to consider Roche drug for a type of vasculitis

23-07-2013

UK drug watchdog the National Institute for Health and Care Excellence (NICE) has today (July 23) published…

BiotechnologyEuropeMabTheraOncologyPharmaceuticalPricingRare diseasesRegulationRoche

Celgene gets negative NICE view on Revlimid in rare blood cancer; presents new data in newly-diagnosed MM

11-07-2013

US biotech firm Celgene (Nasdaq: CELG) today (July 11) expressed disappointment at the preliminary decision…

BiotechnologyCelgeneEuropeOncologyPricingRare diseasesRegulationResearchRevlimid

Regulatory news for Hyperion's Ravicti and Seattle Genetics' Adcetris

04-02-2013

The US Food and Drug Administration on Friday approved Hyperion Therapeutics' (Nasdaq: HPTX) Ravicti…

AdcetrisBiotechnologyHyperion TherapeuticsNorth AmericaOncologyPatentsPharmaceuticalRare diseasesRavictiRegulationSeattle Genetics

arGEN-X expands antibody deal with Shire; initiates ARGX-110 trial in cancer

08-01-2013

Netherlands and Belgium-based preclinical stage biotech firm arGEN-X, specialized in the discovery and…

arGEN-XARGX-110BiotechnologyLicensingOncologyRare diseasesResearchShire

Licensing deals for Amgen/ImmunoGen and Shire/Arrowhead

20-12-2012

US biotechnology company ImmunoGen (Nasdaq), which develops anticancer therapeutics using its Targeted…

AmgenArrowhead ResearchBiotechnologyImmunoGenLicensingOncologyPharmaceuticalRare diseasesShire

News briefs: Auxilium/Pfizer accord; Novartis Signifor and RLX030 developments

08-11-2012

US specialty drugmaker Auxilium Pharmaceuticals' (Nasdaq: AUXL) shares fell 7.2% to $18.60 at close of…

Auxilium PharmaceuticalsBiotechnologyCardio-vascularLicensingNovartisOncologyPfizerPharmaceuticalRare diseasesResearchRLX030SigniforXiaflexXiapex

Cell Therapeutics initiates launch of Pixuvri in Europe

12-09-2012

Following the European approval of the drug this spring (The Pharma Letter May 14), US biotech firm Cell…

BiotechnologyCell TherapeuticsEuropeMarkets & MarketingOncologyPixuvriRare diseases

Cell Therapeutics prepares for Pixuvri launch; posts 2nd-qtr results

01-08-2012

US biotech firm Cell Therapeutics (Nasdaq: CTIC) yesterday reported second-quarter 2012 financial results…

BiotechnologyCell TherapeuticsFinancialMarkets & MarketingOncologypacritinibPixuvriRare diseasesResearchtosedostat

CHMP positive on first gene therapy, Glybera; and more opinions

23-07-2012

Reversing an earlier negative opinion (The Pharma Letter April 22), the European Medicines Agency's Committee…

AdcetrisBiotechnologyCelgeneDacogenEuropeGlyberaIstodaxJanssen-CilagJohnson & JohnsonOncologyPfizerPharmaceuticalRare diseasesRegulationTakeda PharmaceuticalsuniQureXalkori

News briefs: US priority review for regorafenib; Ph IIb blisibimod data

29-06-2012

Bayer HealthCare, a US unit of Germany's Bayer (BAYN: DE) and partner Onyx Pharmaceuticals (Nasdaq: ONXX)…

Anthera PharmaceuticalsBayerBiotechnologyblisibimodOncologyOnyx PharmaceuticalsPharmaceuticalRare diseasesregorafenibRegulationResearch

Germany's IQWiG finds in favor of Yervoy but not Benlysta or Fampyra

09-05-2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) in the past few days issued a…

BenlystaBiogen IdecBiotechnologyBristol-Myers SquibbEuropeFampyraGlaxoSmithKlineNeurologicalOncologyPharmaceuticalPricingRare diseasesRegulationYervoy

Back to top